Juan Sebastian Hurtado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Sebastian Hurtado has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Cristian C. Serrano-Mayorga
Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia
1 shared publication Daniel C. Tellez-Barros
1 shared publication- Dawit Getachew Assefa
Department of Nursing, College of Health Science and Medicine Dilla University Dilla Ethiopia
1 shared publication Eve Wool
1 shared publication- Franklyn Edwin Prieto Alvarado
Instituto Nacional de Salud, Bogota, Colombia
1 shared publication - Gláucia Cota
Fundação Oswaldo Cruz, Brasil
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Time From Symptom Onset to Treatment Initiation in Visceral Leishmaniasis In Brazil, 2007–2023: A National Notifiable Disease Registry-Based Study
Background: Prompt diagnosis and treatment remain key to global visceral leishmaniasis (VL) control. Despite this, a long gap between symptom onset and treatment initiation has often been reported in different endemic countries.Methods: VL surveillance data were obtained from Brazil’s Sistema de Informação de Agravos de Notificação (SINAN) system (2007–2023). The primary exposure was the number of days between reported symptom onset and the treatment initiation (TTI). Cox regression was used to investigate the impact of TTI on mortality within 12 months of treatment. Findings: A total of 35,186 confirmed cases of primary VL were included. The TTI gap was best described by a log-normal distribution; based on this model, 50%, 75%, and 95% of patients received treatment within 26, 56, and 169 days, respectively. The median (interquartile range, IQR) TTI increased progressively with patients’ age: 21 days (IQR: 12-36) among <15y and 35 days (IQR: 17–73) among ≥15 years. Patients with TTI ≥120 days had a 12-months survival of 0·86 [95% confidence interval (95% CI): 0·83–0·89] compared to 0·89 [95% CI: 0·87–0·92] among those with TTI ≤14 days (P <0·001, log-rank test), and 0·91 [95% CI: 0·90–0·92] among those with TTI between 15–30 days (P=0·001, log-rank test). Age less than 5 years, the South region, and HIV co-infection were associated with increased mortality in the multivariable Cox model. Interpretation: Early presentation was associated with a higher 12-month survival. These findings provide insights into optimising patient management and disease control efforts in Brazil.
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTime From Symptom Onset to Treatment Initiation in Visceral Leishmaniasis In Brazil, 2007–2023: A National Notifiable Disease Registry-Based Study
Background: Prompt diagnosis and treatment remain key to global visceral leishmaniasis (VL) control. Despite this, a long gap between symptom onset and treatment initiation has often been reported in different endemic countries.Methods: VL surveillance data were obtained from Brazil’s Sistema de Informação de Agravos de Notificação (SINAN) system (2007–2023). The primary exposure was the number of days between reported symptom onset and the treatment initiation (TTI). Cox regression was used to investigate the impact of TTI on mortality within 12 months of treatment. Findings: A total of 35,186 confirmed cases of primary VL were included. The TTI gap was best described by a log-normal distribution; based on this model, 50%, 75%, and 95% of patients received treatment within 26, 56, and 169 days, respectively. The median (interquartile range, IQR) TTI increased progressively with patients’ age: 21 days (IQR: 12-36) among <15y and 35 days (IQR: 17–73) among ≥15 years. Patients with TTI ≥120 days had a 12-months survival of 0·86 [95% confidence interval (95% CI): 0·83–0·89] compared to 0·89 [95% CI: 0·87–0·92] among those with TTI ≤14 days (P <0·001, log-rank test), and 0·91 [95% CI: 0·90–0·92] among those with TTI between 15–30 days (P=0·001, log-rank test). Age less than 5 years, the South region, and HIV co-infection were associated with increased mortality in the multivariable Cox model. Interpretation: Early presentation was associated with a higher 12-month survival. These findings provide insights into optimising patient management and disease control efforts in Brazil.
- Open Access
- 10 May 2026
- Published by Elsevier in SSRN Electronic Journal
Regional and National Mortality and Aetiologies of Non-Covid Lower Respiratory Infections in Latin America and the Caribbean, 1990–2023: A Systematic Analysis for the Global Burden of Disease Study 2023
Background: Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality worldwide, with a disproportionate impact in low- and middle-income regions. Reliable, up-to-date burden estimates are essential for informing public health strategies, particularly in Latin America and the Caribbean, where respiratory infections remain a persistent challenge. High incidence strains the healthcare system capacity and quality, while prevention and management strategies remain limited or heterogeneous across countries.Methods: We analysed estimates from the Global Burden of Disease (GBD) 2023 study to quantify the burden of LRTIs in Latin America and the Caribbean between 1990 and 2023. Cause-specific estimates of mortality, incidence, and disability-adjusted life years (DALYs), expressed as years of life lost (YLL) plus years lived with disability (YLD), were extracted from the GBD Results Tool. Estimates were produced following the standardised GBD protocol, coordinated by the Institute for Health Metrics and Evaluation (IHME), which synthesises multiple data sources using validated statistical models.Findings: Globally, LRTIs accounted for 41·0 (36·0–48·0) deaths per 100 000 person-years in 2023, representing a 33·2% decline from 62 (53·0–72·0) per 100 000 in 1990. Within Latin America and the Caribbean, trends were heterogeneous across countries. Mortality rates declined substantially in Chile (from 48·0 [44·1–51·8] to 27·9 [24·1–31·4] deaths per 100 000; annualized rates of change [ARC] -1·63) and Mexico (from 36·3 [33·3–39·8] to 28·2 [24·6–32·3]; ARC -0·76), while reductions were most pronounced among children under five years, notably in Brazil (from 150·6 [131·2–175·2] to 18·5 [15·9–21·3] per 100 000; ARC -6·16) and Chile (from 55·1 [50·6–60·1] to 5·4 [4·3–6·5]; ARC -6·79). DALY rates also declined markedly in several countries, with the largest reductions observed in Peru (from 5771·5 [4896·0–6845·4] to 1629·9 [1357·9–1940·8] per 100 000; ARC -3·76) and Mexico (from 2359·6 [2123·0–2619·1] to 825·5 [727·2–927·7]; ARC -3·13). Following a sustained decline in incidence from 1990 to 2019, the post-COVID-19 era saw a marked reversal across all age groups, with incidence rates rising steadily through 2023, most notably among children under five years in Brazil (ARC +7·919) and Suriname (ARC +8·844), and older adults over 70 years in Cuba (ARC +5·050) and Chile (ARC +5·138). Based on aetiological causes, in 2023 Streptococcus pneumoniae remained the leading agent of LRTI mortality in the region (7·84 [6·99–8·92] deaths per 100 000), followed by Staphylococcus aureus (3·36 [3·02–3·69] deaths per 100 000).Interpretation: LRTIs remain a leading cause of death and disability in Latin America and the Caribbean, yet our findings demonstrate substantial progress in reducing mortality and DALY burden over three decades. We document marked heterogeneity across countries and age groups, with the greatest gains among children under five years old. Shifts in pathogen distribution are evident: S. pneumoniae persists as the leading cause of LRTI mortality, while S. aureus and non-tuberculous mycobacteria (NTM) have emerged as increasingly important contributors. The post-COVID period has reversed prior incidence trends across all age groups, underscoring the vulnerability of regional health systems to pandemic disruptions. These findings highlight the urgent need for sustained investment in vaccination programmes, equitable access to care, and strengthened epidemiological surveillance to reduce the burden of LRTI in the region.
- 10 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRegional and National Mortality and Aetiologies of Non-Covid Lower Respiratory Infections in Latin America and the Caribbean, 1990–2023: A Systematic Analysis for the Global Burden of Disease Study 2023
Background: Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality worldwide, with a disproportionate impact in low- and middle-income regions. Reliable, up-to-date burden estimates are essential for informing public health strategies, particularly in Latin America and the Caribbean, where respiratory infections remain a persistent challenge. High incidence strains the healthcare system capacity and quality, while prevention and management strategies remain limited or heterogeneous across countries.Methods: We analysed estimates from the Global Burden of Disease (GBD) 2023 study to quantify the burden of LRTIs in Latin America and the Caribbean between 1990 and 2023. Cause-specific estimates of mortality, incidence, and disability-adjusted life years (DALYs), expressed as years of life lost (YLL) plus years lived with disability (YLD), were extracted from the GBD Results Tool. Estimates were produced following the standardised GBD protocol, coordinated by the Institute for Health Metrics and Evaluation (IHME), which synthesises multiple data sources using validated statistical models.Findings: Globally, LRTIs accounted for 41·0 (36·0–48·0) deaths per 100 000 person-years in 2023, representing a 33·2% decline from 62 (53·0–72·0) per 100 000 in 1990. Within Latin America and the Caribbean, trends were heterogeneous across countries. Mortality rates declined substantially in Chile (from 48·0 [44·1–51·8] to 27·9 [24·1–31·4] deaths per 100 000; annualized rates of change [ARC] -1·63) and Mexico (from 36·3 [33·3–39·8] to 28·2 [24·6–32·3]; ARC -0·76), while reductions were most pronounced among children under five years, notably in Brazil (from 150·6 [131·2–175·2] to 18·5 [15·9–21·3] per 100 000; ARC -6·16) and Chile (from 55·1 [50·6–60·1] to 5·4 [4·3–6·5]; ARC -6·79). DALY rates also declined markedly in several countries, with the largest reductions observed in Peru (from 5771·5 [4896·0–6845·4] to 1629·9 [1357·9–1940·8] per 100 000; ARC -3·76) and Mexico (from 2359·6 [2123·0–2619·1] to 825·5 [727·2–927·7]; ARC -3·13). Following a sustained decline in incidence from 1990 to 2019, the post-COVID-19 era saw a marked reversal across all age groups, with incidence rates rising steadily through 2023, most notably among children under five years in Brazil (ARC +7·919) and Suriname (ARC +8·844), and older adults over 70 years in Cuba (ARC +5·050) and Chile (ARC +5·138). Based on aetiological causes, in 2023 Streptococcus pneumoniae remained the leading agent of LRTI mortality in the region (7·84 [6·99–8·92] deaths per 100 000), followed by Staphylococcus aureus (3·36 [3·02–3·69] deaths per 100 000).Interpretation: LRTIs remain a leading cause of death and disability in Latin America and the Caribbean, yet our findings demonstrate substantial progress in reducing mortality and DALY burden over three decades. We document marked heterogeneity across countries and age groups, with the greatest gains among children under five years old. Shifts in pathogen distribution are evident: S. pneumoniae persists as the leading cause of LRTI mortality, while S. aureus and non-tuberculous mycobacteria (NTM) have emerged as increasingly important contributors. The post-COVID period has reversed prior incidence trends across all age groups, underscoring the vulnerability of regional health systems to pandemic disruptions. These findings highlight the urgent need for sustained investment in vaccination programmes, equitable access to care, and strengthened epidemiological surveillance to reduce the burden of LRTI in the region.
- Open Access
- 30 September 2025
- Published by Instituto Nacional de Salud - Direccion de Vigilancia y Analisis del Riesgo en Salud Publica in Reporte Epidemiológico Nacional
- Vol. 7 (3) , 1-11
Brote de infección por Acinetobacter baumannii en una institución de salud de alta complejidad, 2023
Antecedentes. Acinetobacter baumannii es un patógeno oportunista de importancia creciente en las infecciones asociadas a la atención en salud, especialmente en unidades de cuidados intensivos (UCI), debido a su elevada capacidad de persistencia ambiental y resistencia a los antimicrobianos. En octubre del 2023 se identificó un brote de A. baumannii en una UCI de alta complejidad en Pereira, Colombia. Metodología. Se realizó un estudio epidemiológico descriptivo con diseño de casos y controles como parte de la investigación de brote. Se incluyeron seis casos confirmados de infección por A. baumannii y veinte controles hospitalizados en la UCI durante el mismo periodo. La información se obtuvo a partir de historias clínicas, registros de laboratorio (cultivo convencional y FilmArray®) y bases de datos institucionales. Se describieron las características clínicas y epidemiológicas, se estimaron las tasas de incidencia y se evaluaron los factores asociados mediante razones de disparidad (OR) con intervalos de confianza del 95 %, utilizando modelos de regresión logística ajustados por edad y sexo. Resultados. Durante el periodo de estudio se identificaron seis casos, con una tasa de incidencia de 4,8 casos por 100 días-paciente. La neumonía asociada a ventilación mecánica fue el tipo de infección más frecuente. El análisis multivariado mostró una asociación significativa entre la localización de la cama y la infección por A. baumannii, destacándose la cama 22 (OR ajustado = 91,9; IC 95 %: 1,01–2 334,1). Se observó una tendencia a mayor riesgo en pacientes con tubo orotraqueal y en aquellos ingresados durante el turno nocturno. Conclusión. El brote estuvo probablemente relacionado con factores ambientales y organizacionales dentro de la UCI, particularmente con la localización del paciente. Los hallazgos resaltan la importancia de integrar el análisis epidemiológico con la evaluación de procesos y del entorno hospitalario para orientar intervenciones oportunas y efectivas.
- 30 September 2025
- Published by Instituto Nacional de Salud - Direccion de Vigilancia y Analisis del Riesgo en Salud Publica in Reporte Epidemiológico Nacional
- Vol. 7 (3) , 1-11
Open AccessBrote de infección por Acinetobacter baumannii en una institución de salud de alta complejidad, 2023
Antecedentes. Acinetobacter baumannii es un patógeno oportunista de importancia creciente en las infecciones asociadas a la atención en salud, especialmente en unidades de cuidados intensivos (UCI), debido a su elevada capacidad de persistencia ambiental y resistencia a los antimicrobianos. En octubre del 2023 se identificó un brote de A. baumannii en una UCI de alta complejidad en Pereira, Colombia. Metodología. Se realizó un estudio epidemiológico descriptivo con diseño de casos y controles como parte de la investigación de brote. Se incluyeron seis casos confirmados de infección por A. baumannii y veinte controles hospitalizados en la UCI durante el mismo periodo. La información se obtuvo a partir de historias clínicas, registros de laboratorio (cultivo convencional y FilmArray®) y bases de datos institucionales. Se describieron las características clínicas y epidemiológicas, se estimaron las tasas de incidencia y se evaluaron los factores asociados mediante razones de disparidad (OR) con intervalos de confianza del 95 %, utilizando modelos de regresión logística ajustados por edad y sexo. Resultados. Durante el periodo de estudio se identificaron seis casos, con una tasa de incidencia de 4,8 casos por 100 días-paciente. La neumonía asociada a ventilación mecánica fue el tipo de infección más frecuente. El análisis multivariado mostró una asociación significativa entre la localización de la cama y la infección por A. baumannii, destacándose la cama 22 (OR ajustado = 91,9; IC 95 %: 1,01–2 334,1). Se observó una tendencia a mayor riesgo en pacientes con tubo orotraqueal y en aquellos ingresados durante el turno nocturno. Conclusión. El brote estuvo probablemente relacionado con factores ambientales y organizacionales dentro de la UCI, particularmente con la localización del paciente. Los hallazgos resaltan la importancia de integrar el análisis epidemiológico con la evaluación de procesos y del entorno hospitalario para orientar intervenciones oportunas y efectivas.
- Open Access
- 11 October 2023
- Published by Hindawi Limited in Case Reports in Infectious Diseases
- Vol. 2023, 1-4
Guillain–Barré Syndrome Post COVID-19 Vaccination with ChAdOx1 nCoV-19 Vaccine: A Colombian Case Report
Background. Adverse events after vaccination against COVID-19 include rare events, such as GuillainBarr syndrome. Study Aims. Documentation of clinical and temporary characteristics of the GuillainBarr syndrome after using anti-COVID-19 ChAdOx1 nCoV-19 vaccine. Case Presentation. An adult, 29-year-old male, without relevant medical history, who developed neuromuscular symptoms nine days after administration of the first dose of anti-COVID-19 ChAdOx1 nCoV-19 vaccine. Results. Symptoms appeared nine days after vaccination, with lower limbs paresthesia. Three days later, paresthesia of upper limbs occurred. The following day, distal weakness of limbs, with standing and gripping difficulties, occurred. The clinical evaluation demonstrated dysarthria, incomplete palpebral closure, bilateral facial, and tongue paresis. The electromyography was compatible with a motor demyelinating polyneuropathy, confirming the diagnosis of the GuillainBarr syndrome. Management with five sessions of plasma exchange was prescribed, with favorable clinical results. Conclusions. Clinical and laboratory tests confirmed the GuillainBarr syndrome and the time elapsed from the date of the vaccine administration to the appearance of initial symptoms, added to the absence of other causes, and allowed to establish that the disease was caused by the vaccination.
- 11 October 2023
- Published by Hindawi Limited in Case Reports in Infectious Diseases
- Vol. 2023, 1-4
Open AccessGuillain–Barré Syndrome Post COVID-19 Vaccination with ChAdOx1 nCoV-19 Vaccine: A Colombian Case Report
Background. Adverse events after vaccination against COVID-19 include rare events, such as GuillainBarr syndrome. Study Aims. Documentation of clinical and temporary characteristics of the GuillainBarr syndrome after using anti-COVID-19 ChAdOx1 nCoV-19 vaccine. Case Presentation. An adult, 29-year-old male, without relevant medical history, who developed neuromuscular symptoms nine days after administration of the first dose of anti-COVID-19 ChAdOx1 nCoV-19 vaccine. Results. Symptoms appeared nine days after vaccination, with lower limbs paresthesia. Three days later, paresthesia of upper limbs occurred. The following day, distal weakness of limbs, with standing and gripping difficulties, occurred. The clinical evaluation demonstrated dysarthria, incomplete palpebral closure, bilateral facial, and tongue paresis. The electromyography was compatible with a motor demyelinating polyneuropathy, confirming the diagnosis of the GuillainBarr syndrome. Management with five sessions of plasma exchange was prescribed, with favorable clinical results. Conclusions. Clinical and laboratory tests confirmed the GuillainBarr syndrome and the time elapsed from the date of the vaccine administration to the appearance of initial symptoms, added to the absence of other causes, and allowed to establish that the disease was caused by the vaccination.